Atlas Venture Fund XI, L.P.'s Form 4 filing
Xilio Therapeutics, Inc.XLO · filed Jan 16, 2024
- Accession no.
- 0001209191-24-001655
- Filed
- Jan 16, 2024, 6:16 PM ET
- Trade date
- Jan 11-12, 2024
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market sales total $3.60K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Atlas Venture Fund XI, L.P.CIK 0001708269 | 10% Owner |
| Atlas Venture Opportunity Fund I, L.P.CIK 0001759241 | 10% Owner |
| Atlas Venture Associates Opportunity I, L.P.CIK 0001780065 | 10% Owner |
| Atlas Venture Associates Opportunity I, LLCCIK 0001780066 | 10% Owner |
| Atlas Venture Associates XI, LLCCIK 0001780067 | 10% Owner |
| Atlas Venture Associates XI, L.P.CIK 0001780068 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 11, 2024 | Common Stock | SSaleDisposed | −1,566 | $0.87F1 | −$1,362.42 | 2,021,836 | Direct | |
| Jan 11, 2024 | Common Stock | SSaleDisposed | −569 | $0.87F1 | −$495.03 | 735,373 | Indirect | |
| Jan 12, 2024 | Common Stock | SSaleDisposed | −1,540 | $0.83 | −$1,278.2 | 2,020,296 | Direct | |
| Jan 12, 2024 | Common Stock | SSaleDisposed | −560 | $0.83 | −$464.8 | 734,813 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.85 to $0.9499 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.